# GNMX (Corgi Genomics & Precision Medicine ETF)

Corgi · Thematic ETFs · data as of Sep 18, 2026

GNMX holds 58 stocks, and 73% of its weight is outside the S&P 500.

## Key facts

- GNMX, already in the S&P 500: 26.7%, as of Sep 18, 2026.
- GNMX, active share vs the S&P 500: 99.4%, as of Sep 18, 2026.
- GNMX, top ten holdings: 45.1%, as of Sep 18, 2026.
- GNMX, total return, since launch: +41.2%, as of Sep 18, 2026.
- GNMX, net assets: $3m (the issuer’s own daily fund list, as of Sep 18, 2026).
- GNMX, expense ratio: 0.35% (485BPOS XBRL, Apr 30, 2026).

## GNMX over each window to Sep 18, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | +29.7% | +2.3% | +27.4 pts | +32.2 pts |
| Since launch | +41.2% | +4.3% | +36.9 pts | +37.4 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Genomics and gene editing | ETFIQ, editorial |
| Launched | May 6, 2026 | ETFIQ |
| Already in the S&P 500, by weight | 26.7% | ETFIQ |
| Active share vs the S&P 500 | 99.4% | ETFIQ |
| Already in the Nasdaq-100, by weight | 8.5% | ETFIQ |
| Active share vs the Nasdaq-100 | 99.3% | ETFIQ |
| Top ten holdings weight | 45.1% | ETFIQ |
| Holdings | 58 | ETFIQ |
| Holdings published for | Sep 18, 2026 | the issuer’s daily file |
| Top holdings | Thermo Fisher Scientific Inc 8.6%, Moderna Inc 7.0%, Vertex Pharmaceuticals Inc 5.9%, Illumina Inc 4.4%, Guardant Health Inc 3.9%, 10X Genomics Inc 3.4%, Revolution Medicines Inc 3.3%, Genmab A/S 2.9%, Incyte Corp 2.9%, Twist Bioscience Corp 2.9% | ETFIQ |
| Net assets | $3m | the issuer’s own daily fund list, as of Sep 18, 2026 |
| Below its all-time high | −1.0% | ETFIQ |
| Expense ratio | 0.35% | 485BPOS XBRL, Apr 30, 2026 |
| Fee for the part that differs from the S&P 500, active expense ratio | 0.35% | ETFIQ |
| Closest funds by holdings overlap | GNOM 47%, HLTH 36%, ARKG 35%, WDNA 32%, IDNA 31% | ETFIQ |

## Questions

### How much of GNMX is in S&P 500 companies?

By its holdings published by its issuer for Sep 18, 2026, 27% of GNMX by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different.

### What does GNMX hold?

58 positions as published by its issuer for Sep 18, 2026, with the top ten at 45% of the fund. The largest are Thermo Fisher Scientific Inc at 8.6%, Moderna Inc at 7.0%, Vertex Pharmaceuticals Inc at 5.9%.

### Has GNMX beaten the S&P 500?

Over the year to Sep 18, 2026 GNMX returned +41.2% with distributions reinvested, against +4.3% for the S&P 500, so it finished ahead of the index by 36.9 points.

### What does GNMX cost?

The prospectus expense ratio is 0.35% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.35%.


## Cite this page

ETFIQ, GNMX, data as of Sep 18, 2026. https://etfiq.com/funds/gnmx
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/gnmx  ·  JSON: https://etfiq.com/funds/gnmx.json